Immunotherapy Resistance: New Study Reveals Mechanism
- For many cancer patients,immunotherapy offers a beacon of hope,harnessing the power of the body's own immune system to fight the disease.
- Researchers from Moffitt Cancer center, the Karolinska Institutet, and the University of Texas MD Anderson cancer Center discovered that as cancer cells infiltrate and damage tumor-associated nerves, they...
- The study meticulously examined patient samples - including those from recent neoadjuvant therapy trials - and utilized preclinical models of cutaneous squamous cell carcinoma, melanoma, gastric cancer, and...
How Cancer Hijacks Your Nerves to Evade Immunotherapy
Table of Contents
Published August 21,2025
The Unexpected Link Between Nerves and Cancer Resistance
For many cancer patients,immunotherapy offers a beacon of hope,harnessing the power of the body’s own immune system to fight the disease. However, a significant number of patients don’t respond to this treatment. Now, a groundbreaking international study published in Nature reveals a surprising reason why: cancer’s ability to damage nearby nerves, effectively shielding itself from immune attack.
Researchers from Moffitt Cancer center, the Karolinska Institutet, and the University of Texas MD Anderson cancer Center discovered that as cancer cells infiltrate and damage tumor-associated nerves, they unleash an inflammatory response. This response doesn’t help fight the cancer; instead, it creates a protective barrier, diminishing the effectiveness of anti-PD-1 immunotherapy.
How Nerve Damage Suppresses the Immune Response
The study meticulously examined patient samples - including those from recent neoadjuvant therapy trials – and utilized preclinical models of cutaneous squamous cell carcinoma, melanoma, gastric cancer, and pancreatic cancer. The findings revealed that cancer cells degrade the myelin sheath, the protective covering of nerves. This injury triggers the release of inflammatory signals, specifically IL-6 and type 1 interferons. While the body initially attempts to repair this nerve damage, the persistent inflammation ultimately creates a chronically suppressive habitat around the tumor, hindering the immune system’s ability to recognize and attack cancer cells.
“Our findings demonstrate that cancer-induced nerve injury is not just a bystander effect, it directly shapes the immune environment in ways that allow tumors to evade treatment. Importantly, we also found that this process is reversible,” explained Kenneth Tsai, M.D., Ph.D., co-corresponding author of the study and co-director of Moffitt’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence.
Reversing Resistance: Potential New Treatment Strategies
The research team explored several approaches to disrupt this damaging cycle and restore the effectiveness of immunotherapy. They found that removing the nerves transmitting pain signals, blocking key neuronal injury signals, or combining anti-PD-1 therapy with drugs that target the IL-6 pathway could overcome resistance. This suggests that targeting the communication between cancer, nerves, and the immune system could be a powerful new strategy.
“This work highlights a new role for the nervous system in cancer progression and resistance to therapy,” Tsai stated. “By targeting the signaling that follows nerve injury, we might potentially be able to restore the immune system’s ability to fight cancer.”
implications for Cancer Treatment and Future Research
This discovery is notably significant because many cancer types are known to invade and grow along nerves, often correlating with a poorer prognosis. Targeting nerve-related inflammation could thus improve outcomes for a broad range of patients. The researchers emphasize that this is an exmaple of how a deeper understanding of the complex interplay between cancer, the nervous system, and the immune system can reveal previously unknown vulnerabilities.
Funding and Resources
This research was supported by the national Institutes of Health (CA016672, P30CA016672 and P30-CA076292).
Journal Reference: Baruch, E. N., et al. (2025) Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. doi.org/10.1038/s41586-025-09370-8.